Craig R Gibeau

This inventor holds 24 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 19 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck Sharp + Dohme Corp., Merck Sharp & Dohme LLC, E Ink Corporation. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Craig R Gibeau. Retrieved from https://idiyas.com/inventor/craig-r-gibeau

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 19 (Patent Applications = 14)

Average Co-Inventor Count = 8.7

ph-index = 4

Forward Citations = 55(Granted Patents)

Location History:

Arlington, MA (US) (2011)
Natick, MA (US) (2014 - 2015)
Boston, MA (US) (2019)
Holliston, MA (US) (2018 - 2020)
Northborough, MA (US) (2021)

Company Filing History:

19 out of 2,405

Merck Sharp + Dohme Corp.

patents

3 out of 70

Merck Sharp & Dohme LLC

Msd International Gmbh

patents

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Electrophoretic Media

Charge Control Agents

PRMT5 Inhibitors

Indoleamine 2,3-Dioxygenase

Tricyclic Compounds

IRAK4 Activity

P53 Activity

Aminopyrimidinones

Substituted Piperidines

Carboxamide Inhibitors

Thienopyrazine Inhibitors

Pyrazolopyrimidine Inhibitors

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12699288 - Electrophoretic media comprising electrophoretic particles and a combination of charge control agents (2026-08-04),

2. 12595262 - PRMT5 inhibitors (2026-04-07),

3. 12595248 - PRMT5 inhibitors (2026-04-07),

4. 12583871 - PRMT5 inhibitors (2026-03-24),

5. 12441730 - PRMT5 inhibitors (2025-10-14),

6. 12275729 - Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2025-04-14),

7. 12173026 - PRMT5 inhibitors (2024-12-24),

8. 10995085 - Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-05-04),

9. 10647705 - Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2020-05-12),

10. 10508108 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-12-17),

11. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),

12. 10329295 - Pyrrolotriazine inhibitors of IRAK4 activity (2019-06-25),

13. 10329294 - Pyrazolopyrimidine inhibitors of IRAK4 activity (2019-06-25),

14. 10155765 - Carboxamide inhibitors of IRAK4 activity (2018-12-18),

15. 10040802 - Thienopyrazine inhibitors of IRAK4 activity (2018-08-07),

Title: Spotlight on Inventor Craig R Gibeau: Pioneering IDO Inhibitors

Introduction:

Craig R Gibeau, a distinguished inventor based in Natick, MA, has made significant contributions to the field of pharmaceuticals with his groundbreaking inventions. With an impressive portfolio of 17 patents to his name, Gibeau continues to push the boundaries of innovation in the healthcare industry.

Latest Patents:

One of Gibeau's recent patents showcases his expertise in developing substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors. These compounds, represented by formula (I), have shown promise in the treatment and prevention of IDO-associated diseases and disorders. The patent also delves into the various uses and compositions of these compounds, signaling a new era in pharmaceutical research.

Career Highlights:

Gibeau's professional journey has been enriched by his tenure at renowned companies such as Merck Sharp & Dohme Corporation and Merck GmbH. His innovative spirit and dedication to scientific advancement have been pivotal in shaping the pharmaceutical landscape, earning him accolades among his peers and collaborators.

Collaborations:

Throughout his career, Gibeau has collaborated with industry experts like Michael D Altman and Jongwon Lim, enhancing the exchange of ideas and expertise in the pursuit of cutting-edge solutions. These collaborations have not only enriched Gibeau's work but have also propelled the development of revolutionary pharmaceutical technologies.

Conclusion:

In conclusion, Craig R Gibeau stands as a beacon of innovation in the realm of pharmaceutical inventions, with a remarkable track record of patents that attest to his ingenuity and dedication. His pioneering research in IDO inhibitors serves as a testament to his commitment to advancing healthcare solutions and improving patient outcomes. Gibeau's contributions continue to inspire and shape the future of pharmaceutical innovation, paving the way for transformative discoveries in the field.

Profile summary based on public USPTO records.